Full metadata record

DC Field Value Language
dc.contributor.authorKhan, Mohammad Ashrafuddin-
dc.contributor.authorEl-Gamal, Mohammed I.-
dc.contributor.authorOh, Chang-Hyun-
dc.date.accessioned2024-01-20T02:04:21Z-
dc.date.available2024-01-20T02:04:21Z-
dc.date.created2022-01-10-
dc.date.issued2017-02-
dc.identifier.issn1389-5575-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/123103-
dc.description.abstractB-RAF gene is a component of the MAPK pathway that plays a very important role in cell division, survival, proliferation, and many other cellular functions. Mutations of the B-RAF (such as V600E-B-RAF) lead to melanoma, which is one of the leading causes of death worldwide. R&D progress is being done aiming at improved therapy in the future. The existing melanoma therapy is left out with poor overall survival, drug resistance, and many side effects. With the recent approval of new drugs, there is a hope for melanoma patients for complete cure and better life quality. However, there is still a need for improved, safe, and complete therapy for advanced melanoma. This review describes melanoma caused by V600E-B-RAF gene mutation, its pathway, drugs available and recently approved drugs, and future prospects to be overcome.-
dc.languageEnglish-
dc.publisherBENTHAM SCIENCE PUBL LTD-
dc.subjectCYCLIN D1 EXPRESSION-
dc.subjectMETASTATIC MELANOMA-
dc.subjectBRAF MUTATIONS-
dc.subjectBRAF(V600E) INHIBITION-
dc.subjectPTEN/MMAC1 ALTERATIONS-
dc.subjectDABRAFENIB GSK2118436-
dc.subjectCOMBINATION THERAPY-
dc.subjectACQUIRED-RESISTANCE-
dc.subjectMALIGNANT-MELANOMA-
dc.subjectSIGNALING PATHWAY-
dc.titleA Progressive Review of V600E-B-RAF-Dependent Melanoma and Drugs Inhibiting It-
dc.typeArticle-
dc.identifier.doi10.2174/1389557516666160622213142-
dc.description.journalClass1-
dc.identifier.bibliographicCitationMINI-REVIEWS IN MEDICINAL CHEMISTRY, v.17, no.4, pp.351 - 365-
dc.citation.titleMINI-REVIEWS IN MEDICINAL CHEMISTRY-
dc.citation.volume17-
dc.citation.number4-
dc.citation.startPage351-
dc.citation.endPage365-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000399579900004-
dc.identifier.scopusid2-s2.0-85012067997-
dc.relation.journalWebOfScienceCategoryChemistry, Medicinal-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeReview-
dc.subject.keywordPlusCYCLIN D1 EXPRESSION-
dc.subject.keywordPlusMETASTATIC MELANOMA-
dc.subject.keywordPlusBRAF MUTATIONS-
dc.subject.keywordPlusBRAF(V600E) INHIBITION-
dc.subject.keywordPlusPTEN/MMAC1 ALTERATIONS-
dc.subject.keywordPlusDABRAFENIB GSK2118436-
dc.subject.keywordPlusCOMBINATION THERAPY-
dc.subject.keywordPlusACQUIRED-RESISTANCE-
dc.subject.keywordPlusMALIGNANT-MELANOMA-
dc.subject.keywordPlusSIGNALING PATHWAY-
dc.subject.keywordAuthorCancer-
dc.subject.keywordAuthordrug-
dc.subject.keywordAuthorkinase inhibitors-
dc.subject.keywordAuthormelanoma-
dc.subject.keywordAuthorV600E-B-RAF-
Appears in Collections:
KIST Article > 2017
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE